Pharmaceutical Technology

DECEMBER 7, 2022

Alongside the discourse on what the positive study results could mean for patients, researchers are prioritising the development of more biomarkers to identify potential responders and improve patient outcomes. Lecanemab is an amyloid antibody that targets oligomers and protofibrils of amyloid. Amyloid-targeting therapies.

Development 264

Development Drugs Clinical Trials Clinical Trials 264

BioPharma Reporter

JUNE 24, 2021

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates (ADCs), has expanded its research collaboration and license agreement with LegoChem Biosciences Inc (LCB).

DNA 55

DNA Licensing Licensing Antibody 55

Pharmaceutical Technology

DECEMBER 7, 2022

Alongside the discourse on what the positive study results could mean for patients, researchers are prioritising the development of more biomarkers to identify potential responders and improve patient outcomes. Lecanemab is an amyloid antibody that targets oligomers and protofibrils of amyloid. Amyloid-targeting therapies.

Development 246

Development Drugs Clinical Trials Clinical Trials 246

XTalks

DECEMBER 28, 2023

BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Hoffmann-La Roche and Bharat Biotech are in the second and third positions, respectively.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

Roots Analysis

JANUARY 21, 2024

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Vaccine 130

Vaccine Vaccination Antibody DNA 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Vaccine 130

Vaccine Vaccination Containment Immune Response 130

Pharmaceutical Technology

FEBRUARY 24, 2023

Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology. The drug candidate is a bi-specific monoclonal antibody that targets EGFr and cMet with exon-20 insertion. It is administered as an intravenous and subcutaneous infusion.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

Delveinsight

DECEMBER 1, 2020

BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research. US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link’s antibody test, AccuFind COVID-19 IgG, in a healthcare setting.

Antibody 52

Antibody DNA Clinical Trials Clinical Trials 52

Pharmaceutical Technology

SEPTEMBER 7, 2022

Biopharma companies are under pressure to do more with less in the production of monoclonal antibody (mAb) therapies. Effectively clearing DNA early in the process before Protein A can lower host cell proteins (HCPs) in the Protein A eluate. Efficiencies in processes are highly sought. Dr El-Sabbahy: “Yes. mediated hitch?

Protein 130

Protein Production DNA Manufacturing 130

Worldwide Clinical Trials

JULY 8, 2024

Radiolabeled Antibodies : Various antibodies are being radiolabeled to target specific cancer antigens, enhancing both diagnostic accuracy and therapeutic efficacy. Genetic Factors : Certain genetic mutations, such as those in DNA repair genes, can affect how cells respond to radiation.

Hormones 130

Hormones Regulation Clinical Trials Clinical Trials 130

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0

DNA 40

DNA Vaccine Vaccination Immune Response 40

Roots Analysis

FEBRUARY 27, 2024

Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of ADCs pipeline. In nature, they are made by a group of bacteria known as actinomycetes.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Find Me Cure

OCTOBER 13, 2019

This Breast Cancer Awareness Month we’d like to talk about emerging areas in metastatic breast cancer treatment since clinical research has come so far in recent years. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials.

Development 52

Development DNA Clinical Trials Clinical Trials 52

Delveinsight

MARCH 2, 2021

To sum it, Chinook will manage clinical development and commercialization of product candidates while Evotec will be eligible for an undisclosed upfront payment, research funding, progress-dependent milestone payments, and tiered royalties on net sales for targets identified through the collaboration.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

pharmaphorum

FEBRUARY 5, 2021

DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing. That’s been achieved thanks to a group of 10 million people worldwide who have agreed to allow their genetic data to be used for research.

Genetics 52

Genetics DNA Life Science Clinical Trials 52

Delveinsight

AUGUST 6, 2020

The Indian company informed that the DNA vaccine was well tolerated in the first stage of the adaptive phase 1/2 trial. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. Scientists have already isolated many highly potent neutralizing antibodies from patients who recovered from COVID-19.

Allergies 53

Allergies Vaccine Vaccination Gene Therapy 53

The Pharma Data

DECEMBER 2, 2020

Twist intends to use the net proceeds to be received by it in the offering, along with its existing cash, cash equivalents and short-term investments to increase its operational capacity, tooling, and scaling an additional manufacturing location to support its growth in NGS, synbio, DNA prep, its pharmaceutical biologics antibody platform and IgG products; (..)

Containment 52

Containment DNA Sales Antibody 52

Roots Analysis

FEBRUARY 15, 2022

Over time, medical researchers have been able to further develop their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing Containment 52

Intouch Solutions

SEPTEMBER 27, 2024

With the theme “Shaping the Future of Anticancer Therapies,” ESMO 2024 saw record crowds and focused on advancements across immuno-oncology, antibody drug conjugates (ADCs) and numerous malignancies. We heard about monoclonal antibodies, bispecifics and antibody-drug conjugates, and many of these are being used in combination.

DNA 59

DNA Trials Antibody Marketing 59

The Pharma Data

SEPTEMBER 1, 2020

with whom Roche has a global distribution agreement and had also launched a Rapid Antibody Test in July. If the target antigen is present in sufficient concentrations in the sample, it will bind to specific antibodies and generate a visually detectable signal on the test strip, typically with results ready in 15 minutes.

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. The research encompasses two projects.

Vaccine 40

Vaccine Vaccination Development Medicine 40

The Pharma Data

JANUARY 13, 2021

” The Johnson & Johnson vaccine also would be hardier than either of the already approved vaccines because it relies on DNA technology rather than messenger RNA to prompt an immune system response. More than 90% of participants mounted an immune response within a month, and all had levels of neutralizing antibodies by day 57.

Vaccine 40

Vaccine Vaccination Trials Immune Response 40

XTalks

SEPTEMBER 30, 2020

While it remains unclear why some people become more gravely ill than others when infected with the SARS-CoV-2 virus that causes COVID-19, researchers have found that an immune deficiency may be part of it. The team sequenced DNA from 659 critically ill COVID-19 patients and 534 controls with mild or asymptomatic disease.

Antibody 135

Antibody Genetics Research In-Vitro 135

The Pharma Data

JULY 11, 2021

Hereditary angioedema is a lifelong condition and research shows that concerns about another attack can limit the way patients lead their lives,” said Prof. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. All antibody titres were low. Markus Magerl, M.D.,

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

JUNE 28, 2021

With the first and only approved targeted alpha therapy Xofigo and its unique experience across the value chain from early research to supply, Bayer has successfully established TAT as part of standard of care for prostate cancer patients globally. Compared to beta radiation, alpha radiation has a higher potency and shorter range.

Licensing 52

Licensing Licensing Medicine Development 52

Roots Analysis

NOVEMBER 3, 2023

NAD + is involved in a wide range of cellular processes, including energy metabolism, DNA repair, and gene expression. There are several types of NAMPT inhibitors, including small molecules, peptides, and antibodies. NAMPT inhibitors work by blocking the activity of NAMPT, which in turn reduces the production of NAD +. Ronit holds a B.

Development 40

Development Drugs Trials FDA Approval 40

Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. This response was also seen in the RV 144 trial, she notes.

Vaccine 293

Vaccine Vaccination Antibody Trials 293

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: DNA polymerase compositions. The majority of DNA replication is performed by Pol δ and Pol ε.

DNA 130

DNA Antibody Vaccine Vaccination 130

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Monoclonal antibody drugs for cancer. Treatment with monoclonal antibodies also helps immune systems defend against cancer.

Antibody 130

Antibody Drugs DNA Vaccine 130

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Transcription of the cap gene is initiated from a single promoter termed p40.

Gene 262

Gene Gene Therapy Genetics DNA 262

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccine Vaccination Dermatology 246

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. bluebird bio is also developing drugs based on DNA and retro-virus vectors.

Gene Therapy 246

Gene Therapy DNA Gene Genetics 246

Pharmaceutical Technology

FEBRUARY 3, 2023

Researchers have relentlessly worked through the barriers to create lifechanging treatments for patients in need. “As The established method for this process is a triple transfection using three different DNA plasmids. For example, researchers have developed a two-plasmid cotransfection system.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 263

Antibody DNA Research Development 263

The Pharma Data

APRIL 30, 2021

On a GAAP basis, research and development expense was 13.7 a leading clinical-stage CRISPR genome editing biotechnology company, announced that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Research and development.

Botox 40

Botox Production Development Cosmetics 40